Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations

被引:11
|
作者
Rabacchi, Claudio [1 ]
Bigazzi, Federico [2 ,3 ]
Puntoni, Mariarita [2 ,3 ]
Sbrana, Francesco [2 ,3 ]
Sampietro, Tiziana [2 ,3 ]
Tarugi, Patrizia [1 ]
Bertolini, Stefano [4 ]
Calandra, Sebastiano [5 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Life Sci, Modena, Italy
[2] Fdn Toscana Gabriele Monasterio, Lipoapheresis Unit, Pisa, Italy
[3] Fdn Toscana Gabriele Monasterio, Ctr Inherited Dyslipidemias, Pisa, Italy
[4] Univ Genoa, Dept Internal Med, Viale Benedetto 15,6, Genoa, Italy
[5] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Via Campi 287, I-41125 Modena, Italy
关键词
Homozygous familial hypercholesterolemia; LDL cholesterol; LDLR gene; APOB gene; Missense mutations; In-frame deletion; DENSITY-LIPOPROTEIN CHOLESTEROL; TRANSFER PROTEIN INHIBITOR; PLACEBO-CONTROLLED TRIAL; APO-B; RECEPTOR GENE; DOUBLE-BLIND; DISEASE; PCSK9; HYPOBETALIPOPROTEINEMIA; RISK;
D O I
10.1016/j.jacl.2016.04.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Homozygous familial hypercholesterolemia is a rare clinical phenotype with a variable expression, which is characterized by extremely elevated plasma low-density lipoprotein (LDL), tendon and skin xanthomas, and a progressive atherosclerosis. In 95% of patients, homozygous familial hypercholesterolemia is due to mutations in low-density lipoprotein receptor (LDLR) gene, which abolish (receptor-negative) or greatly reduce (receptor-defective) LDLR function. OBJECTIVE: The objective of the study was the molecular and phenotypic characterization of 4 siblings with severe hypercholesterolemia. METHODS: The major LDL-related genes (LDLR, APOB, PCSK9, ANGPTL3, APOE, and APOC3) were sequenced. LDLR messenger RNA, isolated from leukocytes, was reverse transcribed and sequenced. RESULTS: The index cases were 24-year-old identical twin sisters with long-standing tendon xanthomas and high low-density lipoprotein cholesterol (LDL-C 10 mmol/L) but no coronary heart disease. They were carriers of 2 LDLR mutations: (1) a previously reported mutation [p.(G335S)] inherited from the mother who had LDL-C level within normal range; (2) a novel 24 bp deletion in exon 8/intron 8 junction inherited from the hypercholesterolemic (LDL-C 6.1 mmol/L) father. The deletion allele encodes an messenger RNA with a partial deletion of exon 8, whose translation product has an in-frame deletion of 17 amino acids [p.(Glu380_Gly396-del)]. Family screening revealed that the 2 siblings of the twin sisters were also compound heterozygotes but had much lower LDL-C levels (8.2 and 7.1 mmol/L). The sequence of potential modifying genes showed that the 2 siblings and the mother of the twin sisters were heterozygous for a rare missense variant of apoB [p.(S2429T)], which might have an LDL-lowering effect. CONCLUSIONS: We report a rare event of 4 siblings found to be compound heterozygotes for 2 LDLR gene mutations but showing a different phenotype severity. The less severely affected siblings were carriers of a rare apoB missense variant. (C) 2016 National Lipid Association. All rights reserved.
引用
收藏
页码:944 / 952
页数:9
相关论文
共 50 条
  • [1] Clinical course of homozygous familial hypercholesterolemia during childhood: report on 4 unrelated patients with homozygous or compound heterozygous mutations in the LDLR gene
    Kubalska, Jolanta
    Chmara, Magdalena
    Limon, Janusz
    Wierzbicka, Aldona
    Prokurati, Sylwester
    Szaplyko, Janina
    Kowalik, Agnieszka
    Mierzewska, Hanna
    Defesche, Joep C.
    Pronicka, Ewa
    JOURNAL OF APPLIED GENETICS, 2008, 49 (01) : 109 - 113
  • [2] Compound Heterozygous Familial Hypercholesterolemia Caused by LDLR Variants
    Pamplona-Cunha, Heloisa
    Medeiros, Marcela Freitas
    Marques Sincero, Thais Cristine
    Back, Isabela de Carlos
    da Silva, Edson Luiz
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 115 (03) : 587 - 589
  • [3] Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient
    Al-Allaf, Faisal A.
    Alashwal, Abdullah
    Abduljaleel, Zainularifeen
    Taher, Mohiuddin M.
    Bouazzaoui, Abdellatif
    Abalkhail, Hala
    Al-Allaf, Ahmad F.
    Athar, Mohammad
    ACTA BIOCHIMICA POLONICA, 2017, 64 (01) : 75 - 79
  • [4] Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
    Hartgers, Merel L.
    Defesche, Joep C.
    Langslet, Gisle
    Hopkins, Paul N.
    Kastelein, John J. P.
    Baccara-Dinet, Marie T.
    Seiz, Werner
    Hamon, Sara
    Banerjee, Poulabi
    Stefanutti, Claudia
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (02) : 390 - 396
  • [5] Clinical course of homozygous familial hypercholesterolemia during childhood: report on 4 unrelated patients with homozygous or compound heterozygous mutations in theLDLR gene
    Jolanta Kubalska
    Magdalena Chmara
    Janusz Limon
    Aldona Wierzbicka
    Sylwester Prokurat
    Janina Szaplyko
    Agnieszka Kowalik
    Hanna Mierzewska
    Joep C. Defesche
    Ewa Pronicka
    Journal of Applied Genetics, 2008, 49 : 109 - 113
  • [6] Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients
    Slimani, Afef
    Jelassi, Awatef
    Jguirim, Imen
    Najah, Mohamed
    Rebhi, Lamia
    Omezzine, Asma
    Maatouk, Faouzi
    Ben Hamda, Khaldoun
    Kacem, Maha
    Rabes, Jean-Pierre
    Abifadel, Marianne
    Boileau, Catherine
    Rouis, Mustapha
    Slimane, Mohamed Naceur
    Varret, Mathilde
    ATHEROSCLEROSIS, 2012, 222 (01) : 158 - 166
  • [7] Screening of LDLR and APOB gene mutations in Mexican patients with homozygous familial hypercholesterolemia
    Hernandez Flores, Teresita De Jesus
    Gonzalez Garcia, Juan Ramon
    Colima Fausto, Ana Gabriela
    Vazquez Cardenas, Norma Alejandra
    Sanchez Lopez, Yoaly
    Zarate Morales, Cesar Augusto
    Magana Torres, Maria Teresa
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 693 - 701
  • [8] PHENOTYPIC DIFFERENCES OF PATIENTS WITH MOLECULARLY DEFINED APOB AND LDLR DEFECTIVE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Vogt, A.
    Keller, C.
    Heigl, C.
    Weiss, N.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 166 - 166
  • [9] Genetic screening for homozygous and heterozygous familial hypercholesterolemia
    Izar, Maria C.
    Machado, Valeria A.
    Fonseca, Francisco A.
    APPLICATION OF CLINICAL GENETICS, 2010, 3 : 147 - 157
  • [10] Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
    Baum, Seth J.
    Soifer, Daniel
    Duell, P. Barton
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2016, 17 (1-2) : 17 - 25